Genomic assays built on Predicine’s proprietary GeneRADAR next generation liquid biopsy platform and DeepSEA machine learning platform. It measures cancer-associated genomic blueprint (DNA) and functional biology (RNA) in a single tube of blood sample.
Predicine introduces urine-based liquid biopsy to broaden cancer patients’ access to genomic profiling. Urine-based cfDNA can be more robust in variant detection than blood-based cfDNA in bladder cancer.
Through our network of CLIA/CAP certified facilities in California and Shanghai, Predicine partners with leading biopharmaceutical companies to support biomarker-driven global clinical trials.
“Liquid biopsy is the future of precision medicine. Our work with Predicine’s liquid biopsy platform is very encouraging for the field of liquid biopsy and supports its clinical application for patient care.”
Ready to streamline your precision oncology clinical research programs? Submit your information via the form below and we’ll follow up shortly.